$MRNA

The FDA approved new COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for 2026-27, targeting current variants. Moderna received approval for two vaccines. Distribution will be limited to specific age groups and high-risk individuals, with availability expected in the fall.

Palo Alto Networks (PANW), American Airlines (AAL), and Moderna (MRNA) reached 52-week highs. PANW rose 3% after Wells Fargo and BTIG raised price targets to $420 and $380, respectively. AAL gained 0.44% on strong travel demand and lower oil prices. MRNA climbed 3% on its expanding drug pipeline and AI-driven research. Retail sentiment varied for the stocks.

Moderna (MRNA) shares fell 2.9% after a Rothschild & Co analyst downgraded the stock to Sell, citing valuation concerns. The analyst raised the price target to $81, implying a 46% downside from the previous close of $150.81. This follows positive Phase 3 trial results for Moderna's cancer vaccine candidate, though the analyst deemed the market's reaction overexuberant. The stock later recovered slightly to $146.24.

Moderna (MRNA) shares are down 18% from their 52-week high of $176.66, trading at $144.83. The decline follows a $2B convertible notes offering and BioNTech's mRNA trial failure. Analysts project $1B+ in oncology sales by 2030, with mixed technical signals. ESMO 2026 data on Oct 26-27 is a key catalyst. Revenue has fallen from $19.26B (FY2022) to $1.94B (FY2025).

Tyson Foods fell 7% after cutting fiscal 2026 guidance. Meta rose 3% on AI model launch. Dell gained 5% post-earnings. Crypto-related stocks climbed with bitcoin. Robinhood jumped 15% on Deutsche Bank's report. Ciena dropped 9% despite beating estimates. Tesla advanced 6% ahead of Cybercab event. Snowflake surged 22% on strong earnings. HPE slipped 4% with lower-than-expected growth forecast. Broadcom lost 3% on weak revenue outlook. Campbell's fell 9% on lagging guidance. Ultragenyx plunged 44%

Analysts updated price targets for several companies. HC Wainwright cut Ultragenyx's (RARE) target to $25. Needham raised UiPath's (PATH) target to $22. BTIG increased Netskope's (NTSK) target to $18 and Snowflake's (SNOW) to $424. Needham also raised Magnite's (MGNI) target to $30. Cantor Fitzgerald boosted Broadcom's (AVGO) target to $600. Baird increased CrowdStrike's (CRWD) target to $235. Rothschild & Co raised Moderna's (MRNA) target to $81 but downgraded it. B of A cut Sonoco's (SON) targ

Analysts upgraded Broadcom (AVGO) to Outperform with a $490 target, Deere (DE) to Outperform with an $813 target, and Dell (DELL) to Outperform with a $625 target. Moderna (MRNA) was downgraded to Sell with an $81 target. Seaport Research initiated Buy ratings on Devon Energy (DVN), Permian Resources (PR), and Viper Energy (VNOM).

Moderna's 177% stock surge followed positive trial results, highlighting a broader biotech rally driven by consolidation, cancer drug progress, and AI. Biotech funds like IBB and XBI have gained 24% and 33% YTD, respectively, but fund flows remain low. Analysts note attractive valuations and potential long-term AI benefits for the sector.

Moderna's market value surged $45B after positive cancer vaccine data. Ultragenyx gained FDA approval for Genglycos, its first gene therapy. BioMarin acquired Alesta Therapeutics for $275M. AstraZeneca scrapped a Phase 3 lung cancer trial. Argenx reported positive Phase 3 data for Vyvgart. Capricor's CEO indicated FDA willingness to review updated cell therapy submission.

Rothschild & Co. downgraded Moderna (MRNA) to sell, citing overvaluation despite a price target increase to $81. The firm argues the stock's surge, driven by positive cancer vaccine trial results, is overexuberant. Moderna's shares are up 411% year-to-date but fell 2% in premarket trading after the downgrade.